Small-scale mutations are infrequent as mechanisms of resistance in post-PARP inhibitor tumour samples in high grade serous ovarian cancer

Abstract While the introduction of poly-(ADP)-ribose polymerase (PARP) inhibitors in homologous recombination DNA repair (HR) deficient high grade serous ovarian, fallopian tube and primary peritoneal cancers (HGSC) has improved patient survival, resistance to PARP inhibitors frequently occurs. Prec...

Full description

Bibliographic Details
Main Authors: Nikki L. Burdett, Madelynne O. Willis, Ahwan Pandey, Sian Fereday, AOCS Study Group, Anna DeFazio, David D. L. Bowtell, Elizabeth L. Christie
Format: Article
Language:English
Published: Nature Portfolio 2023-12-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-023-48153-x